These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10977451)

  • 1. Class effects of angiotensin-converting enzyme inhibitors.
    Sica DA
    Am J Manag Care; 2000 Feb; 6(3 Suppl):S85-108; quiz S109-11. PubMed ID: 10977451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors and end-organ damage in heart failure.
    Sami M
    Can J Cardiol; 1999 May; 15 Suppl C():19C-23C. PubMed ID: 10380688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical overview of antihypertensive classes--clinically relevant differences: myths or facts? Based on a presentation by Alan H. Gradman, MD.
    Am J Manag Care; 2000 Mar; 6(4 Suppl):S197-210. PubMed ID: 10977460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure?
    Nawarskas JJ; Spinler SA
    Pharmacotherapy; 1998; 18(5):1041-52. PubMed ID: 9758314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing hypertension using combination therapy.
    Frank J
    Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of angiotensin-converting enzyme inhibitors on managed care: economic, clinical, and humanistic outcomes.
    Reeder CE; Gourley GA; Wurtzbacher JD; Reed P
    Am J Manag Care; 2000 Feb; 6(3 Suppl):S112-28, quiz S129-31. PubMed ID: 10977441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of angiotensin converting enzyme inhibition and angiotensin II receptor antagonists in hypertension.
    Conlin PR
    J Med Liban; 2000; 48(6):382-6. PubMed ID: 11503531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Singh RK; Barker S
    Curr Opin Investig Drugs; 2005 Mar; 6(3):269-74. PubMed ID: 15816503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M
    J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH
    Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.